Will We See a New Paradigm for SPAF? Which Patients Are More Likely to Benefit from FXIa Inhibition vs DOACs?
Live from IMS 2026: EXCALIBER-RRMM: First Phase 3 CELMoD Data With MRD-Negative CR as a Dual Primary Endpoint in RRMM
PCSK9 Inhibitors in Primary Prevention: A New Paradigm for Family Physicians
The Evolving Role of High Efficacy, Anti-CD40 Therapeutics for Relapsing Multiple Sclerosis
Review of Biosimilar Therapeutics for Patients with Relapsing Multiple Sclerosis
Highlights from Advanced Curriculum in MS 2026: MS Epidemiology, Pathophysiology, Diagnosis and Misdiagnosis
Highlights from Advanced Curriculum in MS 2026: Therapeutic Update for Multiple Sclerosis
Highlights from Advanced Curriculum in MS 2026: Emerging Therapies
Highlights from Advanced Curriculum in MS 2026: Mitigating Adverse Events with MS Disease Modifying Therapies
Update on Clinical Data and Applications for Anti-CD20 Therapeutics to Treat Relapsing Multiple Sclerosis
EHA2026: New Data on the Management of Anemia in Myelofibrosis
Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease
Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease
Re Engineering B Cell Signaling in Sjögren’s Disease: BAFF/APRIL Blockade as a New Path to Durable Disease Control
Beyond Factor Xa: FXI/XIa Inhibition and the Next Era of Stroke Prevention in Atrial Fibrillation
LIVE from ASCO26: New Data on CelMOD Therapy for Multiple Myeloma
Beyond Factor Xa: FXI/XIa Inhibition and the Next Era of Stroke Prevention in Atrial Fibrillation
Update on TTR Stabilizers in ATTR-CM: New Data from ACC 2026
Does nasal etripamil for PSVT drop blood pressure?
ATTR-CM : Updated epidemiology, diagnosis, sex disparities and latest TTR stabilizer data from 2026 so far!